These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36939927)

  • 1.  Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
    Käsmann L; Eze C; Taugner J; Nieto A; Hofstetter K; Kröninger S; Guggenberger J; Kenndoff S; Flörsch B; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7393-7403. PubMed ID: 36939927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
    Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
    Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
    Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
    Flörsch B; Taugner J; Käsmann L; Kenndoff S; Guggenberger J; Tufman A; Reinmuth N; Duell T; Belka C; Eze C; Manapov F
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3267-3276. PubMed ID: 35915184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
    Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.
    Taugner J; Käsmann L; Eze C; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
    Hofstetter K; Taugner J; Käsmann L; Mansoorian S; Flörsch B; Eze C; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Strahlenther Onkol; 2024 Jul; 200(7):614-623. PubMed ID: 37975883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
    Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
    Barsouk A; Friedes C; Iocolano M; Doucette A; Cohen RB; Robinson KW; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Levin WP; Cengel KA; Bradley JD; Feigenberg SJ; Sun L; Aggarwal C; Langer CJ; Yegya-Raman N
    Clin Lung Cancer; 2024 May; 25(3):e161-e171. PubMed ID: 38195320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
    Zhou Q; Chen M; Jiang O; Pan Y; Hu D; Lin Q; Wu G; Cui J; Chang J; Cheng Y; Huang C; Liu A; Yang N; Gong Y; Zhu C; Ma Z; Fang J; Chen G; Zhao J; Shi A; Lin Y; Li G; Liu Y; Wang D; Wu R; Xu X; Shi J; Liu Z; Cui N; Wang J; Wang Q; Zhang R; Yang J; Wu YL
    Lancet Oncol; 2022 Feb; 23(2):209-219. PubMed ID: 35038429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
    Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
    J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
    Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
    Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
    JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
    Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
    Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
    Balasubramanian A; Onggo J; Gunjur A; John T; Parakh S
    Clin Lung Cancer; 2021 Mar; 22(2):74-82. PubMed ID: 33414053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
    Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.